Biotech Values

[DewDiligence]

TRVI IPOs 7.83M* shares @$10.00:

https://www.globenewswire.com/news-release/2019/05/07/1818708/0/en/Trevi-Therapeutics-Announces-Pricing-of-Initial-Public-Offering.html

Trevi Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Trevi is currently conducting a Phase 2b/3 clinical trial of nalbuphine ER, referred to as the PRISM trial, in patients with severe pruritus associated with prurigo nodularis. Founded in 2011, Trevi Therapeutics is headquartered in New Haven, CT.

*Including simultaneous private placement of 1.5M shares and exercise of underwriter’s option.